FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2746247734> ?p ?o ?g. }

• W2746247734 endingPage "85611" @default.
• W2746247734 startingPage "85599" @default.
• W2746247734 abstract "// Chao He 1, * , Xiaoyun Zhang 1, * , Chuan Li 1 , Wei Peng 1 , Tian-Fu Wen 1 , Lv-Nan Yan 1 , Jiayin Yang 1 and Wusheng Lu 1 1 Department of Liver Surgery and Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China * These authors have contributed equally to this work Correspondence to: Tian-Fu Wen, email: 564974843@qq.com Keywords: recurrent hepatocellular carcinoma, trans-arterial chemoembolization, alpha fetoprotein change, prognosis, hepatectomy Received: February 27, 2017      Accepted: July 18, 2017      Published: August 18, 2017 ABSTRACT Background: There is paucity of information concerning whether AFP change is a predictor of prognosis for recurrent hepatocellular carcinoma (RHCC) patients after trans-arterial chemoembolization (TACE). Methods: A total of 177 RHCC patients who received TACE as first-line therapy were retrospectively analyzed. The patients were classified into three groups according to their pre-TACE and post-TACE AFP levels (group A: AFP decreased, group B: AFP consistent normal, and group C: AFP increased). The recurrence to death survival (RTDS) and overall survival (OS) were estimated by the Kaplan-Meier method, and compared by the log-rank test. Multivariate analyses were performed to identify prognostic factors for OS and RTDS. Results: There was no significant difference among the three groups concerning the baseline characteristics. The median overall survival (OS) was 74.5 months in group A (95% confidence interval (CI): 63.5, 85.6), 64.0 months in group B (95% CI: 52.3, 75.7) and 29.0 months in group C (95% CI: 24.1, 33.9; P<0.001). The median recurrence to death survival (RTDS) was 66.5 months (95% CI: 53.4, 79.6) in group A, 50.4 months (95% CI: 39.5, 61.4) in group B and 17.7 months (95% CI: 13.4, 22.1; P<0.001) in group C. Multivariate analysis revealed that tumor size at resection stage, tumor number at recurrent stage, cycles of TACE, mRECIST response and AFP change after TACE were significant independent risk factors for RTDS and OS. Conclusions: AFP change could predict the prognoses of patients with RHCC who received trans-arterial chemoembolization, which may help clinicians make subsequent treatment decision." @default.
• W2746247734 created "2017-08-31" @default.
• W2746247734 creator A5011926534 @default.
• W2746247734 creator A5025301183 @default.
• W2746247734 creator A5043890633 @default.
• W2746247734 creator A5045176116 @default.
• W2746247734 creator A5053958450 @default.
• W2746247734 creator A5058810009 @default.
• W2746247734 creator A5084923939 @default.
• W2746247734 creator A5085338317 @default.
• W2746247734 date "2017-08-18" @default.
• W2746247734 modified "2023-10-18" @default.
• W2746247734 title "Changes of alpha-fetoprotein levels could predict recurrent hepatocellular carcinoma survival after trans-arterial chemoembolization" @default.
• W2746247734 cites W119326763 @default.
• W2746247734 cites W1587929493 @default.
• W2746247734 cites W1600881103 @default.
• W2746247734 cites W1821077834 @default.
• W2746247734 cites W187055837 @default.
• W2746247734 cites W1898809119 @default.
• W2746247734 cites W1910393182 @default.
• W2746247734 cites W1949921930 @default.
• W2746247734 cites W1980144360 @default.
• W2746247734 cites W1988508343 @default.
• W2746247734 cites W2002906231 @default.
• W2746247734 cites W2009378591 @default.
• W2746247734 cites W2009997577 @default.
• W2746247734 cites W2014613954 @default.
• W2746247734 cites W2015801294 @default.
• W2746247734 cites W2018611190 @default.
• W2746247734 cites W2019644592 @default.
• W2746247734 cites W2024248394 @default.
• W2746247734 cites W2057869441 @default.
• W2746247734 cites W2063086242 @default.
• W2746247734 cites W2079586464 @default.
• W2746247734 cites W2085243896 @default.
• W2746247734 cites W2099132737 @default.
• W2746247734 cites W2099877164 @default.
• W2746247734 cites W2122639635 @default.
• W2746247734 cites W2138979436 @default.
• W2746247734 cites W2144602002 @default.
• W2746247734 cites W2145595073 @default.
• W2746247734 cites W2161032959 @default.
• W2746247734 cites W2170705106 @default.
• W2746247734 cites W2236150109 @default.
• W2746247734 cites W2335299761 @default.
• W2746247734 cites W2408916980 @default.
• W2746247734 cites W2409782737 @default.
• W2746247734 cites W2522695119 @default.
• W2746247734 cites W2531862613 @default.
• W2746247734 cites W2539087186 @default.
• W2746247734 cites W2917837889 @default.
• W2746247734 cites W4211105405 @default.
• W2746247734 doi "https://doi.org/10.18632/oncotarget.20343" @default.
• W2746247734 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5689634" @default.
• W2746247734 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29156744" @default.
• W2746247734 hasPublicationYear "2017" @default.
• W2746247734 type Work @default.
• W2746247734 sameAs 2746247734 @default.
• W2746247734 citedByCount "11" @default.
• W2746247734 countsByYear W27462477342019 @default.
• W2746247734 countsByYear W27462477342020 @default.
• W2746247734 countsByYear W27462477342021 @default.
• W2746247734 countsByYear W27462477342022 @default.
• W2746247734 countsByYear W27462477342023 @default.
• W2746247734 crossrefType "journal-article" @default.
• W2746247734 hasAuthorship W2746247734A5011926534 @default.
• W2746247734 hasAuthorship W2746247734A5025301183 @default.
• W2746247734 hasAuthorship W2746247734A5043890633 @default.
• W2746247734 hasAuthorship W2746247734A5045176116 @default.
• W2746247734 hasAuthorship W2746247734A5053958450 @default.
• W2746247734 hasAuthorship W2746247734A5058810009 @default.
• W2746247734 hasAuthorship W2746247734A5084923939 @default.
• W2746247734 hasAuthorship W2746247734A5085338317 @default.
• W2746247734 hasBestOaLocation W27462477341 @default.
• W2746247734 hasConcept C126322002 @default.
• W2746247734 hasConcept C2778019345 @default.
• W2746247734 hasConcept C2778455285 @default.
• W2746247734 hasConcept C2779609443 @default.
• W2746247734 hasConcept C2911091166 @default.
• W2746247734 hasConcept C38180746 @default.
• W2746247734 hasConcept C44249647 @default.
• W2746247734 hasConcept C71924100 @default.
• W2746247734 hasConcept C90924648 @default.
• W2746247734 hasConceptScore W2746247734C126322002 @default.
• W2746247734 hasConceptScore W2746247734C2778019345 @default.
• W2746247734 hasConceptScore W2746247734C2778455285 @default.
• W2746247734 hasConceptScore W2746247734C2779609443 @default.
• W2746247734 hasConceptScore W2746247734C2911091166 @default.
• W2746247734 hasConceptScore W2746247734C38180746 @default.
• W2746247734 hasConceptScore W2746247734C44249647 @default.
• W2746247734 hasConceptScore W2746247734C71924100 @default.
• W2746247734 hasConceptScore W2746247734C90924648 @default.
• W2746247734 hasIssue "49" @default.
• W2746247734 hasLocation W27462477341 @default.
• W2746247734 hasLocation W27462477342 @default.
• W2746247734 hasLocation W27462477343 @default.
• W2746247734 hasLocation W27462477344 @default.
• W2746247734 hasOpenAccess W2746247734 @default.

• next